# Aflibercept Time-Based T&E Protocol with 8-week Minimum
# Time-based disease progression with visit-based measurements

# Metadata
name: "Aflibercept Time-Based T&E (8-week minimum)"
version: "1.0"
created_date: "2025-06-21"
author: "Calibration Team"
description: "Time-based T&E protocol with NHS-compliant 8-week minimum interval"

# Model type indicator - TIME-BASED
model_type: "time_based"
transition_model: "fortnightly"
update_interval_days: 14  # Disease state updates every 2 weeks

# Protocol parameters - Treat-and-Extend
protocol_type: "treat_and_extend"

# Loading dose phase
loading_dose_injections: 3  # Number of initial monthly injections
loading_dose_interval_days: 28  # Monthly (4 weeks) during loading

# T&E intervals - NHS constraint of 8-week minimum
min_interval_days: 56      # 8 weeks (NHS minimum)
max_interval_days: 112     # 16 weeks maximum
extension_days: 14         # Extend by 2 weeks if stable
shortening_days: 14        # Shorten by 2 weeks if active

# Reference to parameter files (relative to this file)
disease_transitions_file: "parameters/disease_transitions.yaml"
treatment_effect_file: "parameters/treatment_effect.yaml"
vision_parameters_file: "parameters/vision.yaml"
discontinuation_parameters_file: "parameters/discontinuation.yaml"
demographics_parameters_file: "parameters/demographics.yaml"

# Baseline vision distribution - UK real-world
baseline_vision_distribution:
  type: beta_with_threshold
  alpha: 3.5
  beta: 2.0
  min: 5
  max: 98
  threshold: 70
  threshold_reduction: 0.6

# Clinical improvements for enhanced realism
clinical_improvements:
  enabled: true
  use_loading_phase: true
  use_time_based_discontinuation: true
  use_response_based_vision: true
  use_baseline_distribution: false  # Use protocol's beta distribution
  use_response_heterogeneity: true
  
  # T&E-specific: 60% optimal responders (from cost calculator)
  response_types:
    good:
      probability: 0.60    # 60% optimal responders who can extend
      multiplier: 1.8      # Better vision gains
    average:
      probability: 0.30    # 30% moderate responders
      multiplier: 1.0      # Normal vision gains
    poor:
      probability: 0.10    # 10% poor responders
      multiplier: 0.5      # Reduced vision gains
  
  # Discontinuation probabilities
  discontinuation_probabilities:
    1: 0.10   # 10% Year 1
    2: 0.15   # 15% Year 2 
    3: 0.12   # 12% Year 3
    4: 0.08   # 8% Year 4
    5: 0.075  # 7.5% Year 5+
  
  # Vision response parameters
  vision_response_params:
    loading:
      mean: 4.0
      std: 1.5
    year1:
      mean: 1.0
      std: 1.0
    year2:
      mean: 0.0
      std: 1.0
    year3plus:
      mean: -0.3
      std: 1.0

# Target outcomes for validation
target_outcomes:
  year1:
    mean_bcva_change: 6.0    # 5-6 letters expected
    mean_injections: 7.5     # 7-8 injections
  year2:
    mean_bcva_change: 5.0    # Slight decline from peak
    cumulative_injections: 12.5  # ~5 in year 2